"Based on the safety and immunogenicity data of the phase 1 clinical
trial, the company would be given permission for conducting phase 2
clinical trial," an official said on the condition of anonymity.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/expert-panel-recommends-permission-for-phase-1-clinical-trial-of-bharat-biotechs-nasal-vaccine/articleshow/80351613.cms
No comments:
Post a Comment